Navigation Links
BTG to Initiate Multi-Centre TARGET Study Evaluating Dosimetry for 90Y Radioembolisation Therapy in Patients With Hepatocellular Carcinoma
Date:4/2/2016

LONDON, April 2, 2016 /PRNewswire/ --

BTG plc (LSE: BTG), a global specialist healthcare company, today announced plans to initiate the TheraSphere® Advanced Dosimetry Retrospective Global Study Evaluation in Hepatocellular Carcinoma Treatment (TARGET).  The study will evaluate two-compartment dosimetry (normal tissue and tumour absorbed dose) in hepatocellular carcinoma patients in interventional oncology in an effort towards a more personalised approach to 90Y radioembolisation therapy for liver cancer patients.

     (Logo: http://photos.prnewswire.com/prnh/20160203/329110LOGO)

Peter Pattison, BTG General Manager Interventional Oncology, commented "BTG investment in TARGET demonstrates our goal to further tailor TheraSphere® therapy to individual patient liver, tumour and disease characteristics. TARGET will compliment other studies, and will be undertaken in collaboration with leading clinical and industry partners in this field, with the ultimate goal of improving patient outcomes in HCC."

The primary endpoint of the study will determine the correlation between the normal tissue absorbed dose, based on 99mTc-MAA, and ≥Grade 3 hyperbilirubinemia for patients administered TheraSphere®. Secondary endpoints in the TARGET study include: tumour absorbed dose, incidence of serious adverse events, select dose related adverse events, clinical laboratory assessment, objective tumour response and overall survival.  

"The current one-compartment dosimetry method for TheraSphere® incorporates a target absorbed dose to the entire liver and adjusts for liver mass, however a more individualised approach is needed to optimise dosimetry." said Professor Marnix Lam, Nuclear Medicine, UMC Utrecht, Netherlands. "The TARGET retrospective study will collect clinical data with the goal of outlining a two-compartment dosimetry model based on 99mTc-MAA dosimetry and customised software manufactured by Mirada Medical. The objective of the study is to provide treating physicians with clinical data that will allow a more tailored dosimetry approach for treating patients. By taking into account the absorbed dose to tumour and normal liver, physicians will have the opportunity to better personalise 90Y radioembolisation therapy."

BTG plans to initiate the study in July 2016 following IRB and EC approval in the United States and select countries in Europe and Asia.

About BTG Interventional Medicine 

BTG Interventional Medicine is part of BTG plc, a growing international specialist healthcare company. As medicine moves from major surgery to minor procedure, from the systemic to the local, no company endeavours to do more than BTG Interventional Medicine to help doctors in their quest to see more, reach further and treat smarter. Our growing portfolio of Interventional Medicine products is designed to advance the treatment of liver tumours, advanced emphysema, severe blood clots, and varicose veins. To learn more about BTG Interventional Medicine, please visit: www.btg-im.com.

About TheraSphere®  

TheraSphere® 90Y glass microspheres are specifically engineered to carry far greater power than any other 90Y liver-directed cancer therapy, delivering high doses of radiation to liver tumours while sparing normal tissue. The result is a powerful, targeted and well-tolerated therapy that may lead to patients becoming eligible for curative therapies.

In the EU, Singapore, South Korea and Canada, TheraSphere® is approved for the treatment of hepatic neoplasia. In the US, TheraSphere® is approved under a Humanitarian Device Exemption (HDE) for use in radiation treatment or as a neoadjuvant to surgery or transplantation in patients with unresectable hepatocellular carcinoma (HCC) who can have placement of appropriately positioned hepatic arterial catheters.  The device is also indicated for HCC patients with partial or branch portal vein thrombosis/occlusion, when clinical evaluation warrants the treatment.  The effectiveness of this device for this use has not been demonstrated. For full instructions for use and important safety information, please visit http://www.therasphere.com.


'/>"/>
SOURCE BTG Plc
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Rodman & Renshaw Initiates Coverage of RegeneRx Biopharmaceuticals, Inc. with Buy Rating
2. Stealth BioTherapeutics Initiates Phase 2 Clinical Study Of Elamipretide In Fuchs Corneal Endothelial Dystrophy
3. AcelRx Pharmaceuticals Initiates Phase 3 Study of ARX-04 in Patients with Post-Operative Moderate-to-Severe Acute Pain
4. Rigel Initiates Phase 2 Clinical Trial Of Fostamatinib In Autoimmune Hemolytic Anemia
5. Boston Scientific Receives U.S. FDA Approval For Quadripolar Leads And Initiates Global Trial To Expand MRI Labeling To The U.S. And Asia
6. Pulmatrix Initiates European Pilot Bioequivalence Study of PUR0200 for COPD
7. Ionis Pharmaceuticals Announces that GSK has Initiated a Phase 1 Study of IONIS-HBV-L Rx
8. AbbVie Initiates Enrollment of Six Global Phase 3 Clinical Studies for Once-Daily, Pan-Genotypic Hepatitis C Regimen
9. Protagonist Therapeutics Initiates Phase 1 Study with Oral Peptide PTG-100
10. National Institutes of Health Initiates Phase 1 Trial of VRC01LS Anti-HIV Therapeutic Antibody Using Xencors Xtend Fc Technology
11. eFFECTOR Therapeutics Initiates Dosing in Phase 1/2 Clinical Trial of eFT508 in Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2020)... ... ... Each year Therapy and Beyond, a leading ABA provider across Texas, ... for 100+ moms of children with autism. This event allows moms to mingle with ... carefree fun. The highly anticipated 3rd annual North Houston Mom’s Mingle will be held ...
(Date:1/23/2020)... ... January 23, 2020 , ... In the largest ... 102 genes associated with risk for autism. The study also shows significant progress ... disability and developmental delay, conditions which often overlap. The study results are published ...
(Date:1/23/2020)... Calif. (PRWEB) , ... January 23, 2020 , ... ... a Meridian Senior Living assisted living community, has received a deficiency-free ... , “We’re very excited to receive a deficiency-free survey from the State,” said ...
Breaking Medicine Technology:
(Date:1/24/2020)... Ariz. (PRWEB) , ... January 24, 2020 , ... ... is teaming up with celebrity fitness expert and best-selling nutrition author Jorge Cruise ... sugars and intermittent fasting. , “I’m an enthusiastic advocate of intermittent fasting, that ...
(Date:1/23/2020)... ... January 23, 2020 , ... The Icahn School of ... and patient care—today announced the recipients of the first-of-its-kind Distinguished Scholar Award, a ... Medicine. The awards aim to mitigate gender gaps in medical research by supporting ...
(Date:1/23/2020)... , ... January 23, 2020 , ... A January 7 ... options to get rid of them. The article quotes the president of the American ... double-chin are many. They can be caused by a person’s facial structure including an ...
(Date:1/23/2020)... ... January 23, 2020 , ... Worldwide Business with ... Brand Director, Michelle Berger and Vice President of Dairy and Frozen, Jimmy Farber ... is a company that creates organic food and snack options at an affordable price. ...
(Date:1/23/2020)... ... 2020 , ... DelawareBio, a nonprofit trade organization with the ... on gene editing that goes beyond CRISPR technology. To be held Thursday, February ... event will provide an overview of the opportunities and challenges expected in bringing ...
Breaking Medicine News(10 mins):